Skip to main content
Year archive

Purple Biotech Ltd. — 2021 filings

All 82 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2021, sourced directly from the official regulator.

82 Filings
2021 Period
2021 filings (82)
Filing Released Lang
6K: results of the Annual General Meeting of Shareholders of the Company held on December 29, 2021
Declaration of Voting Results & Voting Rights Announcements
2021-12-30 English
6K: results of the Annual General Meeting of Shareholders of the Company held on December 29, 2021
AGM Information
2021-12-30 English
Adjournment of annual general meeting- will be reconvened on, December 29, 2021
Proxy Solicitation & Information Statement
2021-12-23 English
Adjournment of annual general meeting- will be reconvened on, December 29, 2021
AGM Information
2021-12-23 English
Adjournment of annual general meeting- will be reconvened on, December 29, 2021
AGM Information
2021-12-23 English
Adjournment of annual general meeting- will be reconvened on, December 29, 2021
AGM Information
2021-12-23 English
Adjournment of annual general meeting- will be reconvened on, December 29, 2021
AGM Information
2021-12-23 English
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
Regulatory Filings
2021-12-09 English
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
Report Publication Announcement
2021-12-09 English
6K: Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program
Regulatory Filings
2021-12-06 English
6K: Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program
Report Publication Announcement
2021-12-06 English
6K:Company Presentation
Report Publication Announcement
2021-11-17 English
6K:Company Presentation
Report Publication Announcement
2021-11-17 English
Immediate Report of Meeting to be held on December 22,2021,proxy
Proxy Solicitation & Information Statement
2021-11-11 English
Immediate Report of Meeting to be held on December 22,2021,proxy
AGM Information
2021-11-11 English
Immediate Report of Meeting to be held on December 22,2021,proxy
AGM Information
2021-11-11 English
Annual General Meeting of Shareholders to be held on December 22,2021,proxy statment
AGM Information
2021-11-11 English
Annual General Meeting of Shareholders to be held on December 22,2021,proxy statment
Report Publication Announcement
2021-11-11 English
6K Amended Report -Termination of Material Agreement- include incorporation by reference language for the Company’s previous registration statements in the USA
Regulatory Filings
2021-11-10 English
6K Amended Report -Termination of Material Agreement- include incorporation by reference language for the Company’s previous registration statements in the USA
Report Publication Announcement
2021-11-10 English
6K: Financial results for the three-month period ended September 30, 2021
Interim / Quarterly Report Q3 2021
2021-11-04 English
6K: Financial results for the three-month period ended September 30, 2021
Report Publication Announcement
2021-11-04 English
6K:Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
Regulatory Filings
2021-10-26 English
6K:Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
Report Publication Announcement
2021-10-26 English
Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance
Regulatory Filings
2021-10-23 English
Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance
Regulatory Filings
2021-10-23 English
settlement agreement with Lupin
Regulatory Filings
2021-10-14 English
settlement agreement with Lupin
Report Publication Announcement
2021-10-14 English
6K:Termination of distribution agreement with Coeptis regarding the distribution of Consensi® in the U.S.
Regulatory Filings
2021-10-10 English
6K:Termination of distribution agreement with Coeptis regarding the distribution of Consensi® in the U.S.
Regulatory Filings
2021-10-10 English
to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update + Company Presentation
Regulatory Filings
2021-09-13 English
to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update + Company Presentation
Report Publication Announcement
2021-09-13 English
6K: Provides Corporate Update and Reports First Half 2021 Financial Results
Interim / Quarterly Report H1 2021
2021-08-05 English
6K: Provides Corporate Update and Reports First Half 2021 Financial Results
Report Publication Announcement H1 2021
2021-08-05 English
6K:Sales Agreement
Regulatory Filings
2021-06-10 English
6K:Sales Agreement
Regulatory Filings
2021-06-10 English
PROSPECTUS SUPPLEMENT (to Prospectus dated December 13, 2019)
Capital/Financing Update
2021-06-10 English
PROSPECTUS SUPPLEMENT (to Prospectus dated December 13, 2019)
Capital/Financing Update
2021-06-10 English
6K: Financial results for the three-month period ended March 31, 2021
Interim / Quarterly Report Q1 2021
2021-06-10 English
6K: Financial results for the three-month period ended March 31, 2021
Report Publication Announcement Q1 2021
2021-06-10 English
Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
Regulatory Filings
2021-06-06 English
Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
Report Publication Announcement
2021-06-06 English
PR:Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
Report Publication Announcement
2021-05-26 English
PR:Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
Regulatory Filings
2021-05-26 English
6K: Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
Regulatory Filings
2021-05-20 English
6K: Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
Report Publication Announcement
2021-05-20 English
Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
Board/Management Information
2021-05-19 English
Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
Regulatory Filings
2021-05-19 English
6K: Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
Regulatory Filings
2021-04-26 English
6K: Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
Regulatory Filings
2021-04-26 English
PR: Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
Regulatory Filings
2021-04-25 English
PR: Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
Regulatory Filings
2021-04-25 English
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Regulatory Filings
2021-04-19 English
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Report Publication Announcement
2021-04-19 English
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Regulatory Filings
2021-04-13 English
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Report Publication Announcement
2021-04-13 English
6K-Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
Regulatory Filings
2021-03-20 English
6K-Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
Report Publication Announcement
2021-03-20 English
FORM 20-F/A (Amendment No. 1)
Annual Report FY 2020
2021-03-17 English
FORM 20-F/A (Amendment No. 1)
Report Publication Announcement
2021-03-17 English
Annual report for 2020 on form 20F
Annual Report FY 2020
2021-03-16 English
Annual report for 2020 on form 20F
Report Publication Announcement
2021-03-16 English
Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Earnings Release Q1 2021
2021-03-11 English
Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Regulatory Filings
2021-03-11 English
6K: Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
Board/Management Information
2021-03-03 English
6K: Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
Board/Management Information
2021-03-03 English
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
Board/Management Information
2021-03-03 English
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
Report Publication Announcement
2021-03-03 English
Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results
Earnings Release FY 2020
2021-03-02 English
Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results
Report Publication Announcement
2021-03-02 English
Form SC 13G/A - CVI Investments, Inc.
Major Shareholding Notification
2021-02-16 English
Form SC 13G/A - CVI Investments, Inc.
Report Publication Announcement
2021-02-16 English
13G-Morgan Stanley
Major Shareholding Notification
2021-02-08 English
13G-Morgan Stanley
Major Shareholding Notification
2021-02-08 English
Purple Biotech to Present at the B. Riley Oncology Investor Conference
Investor Presentation
2021-01-18 English
Purple Biotech to Present at the B. Riley Oncology Investor Conference
Regulatory Filings
2021-01-18 English
FORM 13G/A-Sabby Management, LLC
Major Shareholding Notification
2021-01-16 English
FORM 13G/A-Sabby Management, LLC
Major Shareholding Notification
2021-01-16 English
6K:updated Company Presentation
Regulatory Filings
2021-01-06 English
6K:updated Company Presentation
Report Publication Announcement
2021-01-06 English
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
Regulatory Filings
2021-01-04 English
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
Report Publication Announcement
2021-01-04 English